SS-31

SS-31, also known as Elamipretide, is a synthetic tetrapeptide that targets mitochondrial cardiolipin to enhance bioenergetics, ATP production, and protect against oxidative damage, with FDA approval for Barth syndrome.

Overview

SS-31 is a tetrapeptide (four amino acids: D‑Arg‑dimethylTyr‑Lys‑Phe‑NH₂) developed by Hazel Szeto and Peter Schiller, part of the Szeto-Schiller (SS) peptide family. It selectively accumulates in the inner mitochondrial membrane (IMM), binding to cardiolipin, a specialized phospholipid critical for mitochondrial structure and electron transport chain function

. This localization allows SS-31 to stabilize respiratory chain complexes, prevent reactive oxygen species (ROS) formation, and enhance ATP synthesis without acting on opioid or surface receptors

.

Mechanism of Action

• Cardiolipin Binding: SS-31 binds cardiolipin to prevent peroxidation, stabilize cristae, optimize electron transport, and minimize electron leakage

  .

• Antioxidant Effects: Dimethyltyrosine residues neutralize ROS directly within mitochondria, protecting proteins and lipids from oxidative damage while preserving physiological redox signaling

  .

• ATP and Bioenergetics: SS-31 improves ADP/ATP exchange via adenine nucleotide translocators, supports ATP synthase function, and enhances mitochondrial respiratory efficiency, translating to improved energy production in metabolically active tissues

  .

• Cellular Health: Reduces apoptosis, maintains mitochondrial membrane potential, supports mitochondrial dynamics, and may modulate neurovascular and muscle performance pathways

  .

Therapeutic Benefits and Applications

• Barth Syndrome: FDA-approved under the brand name Forzinity for patients ≥30 kg. Demonstrated improvements in muscle strength, 6-minute walk distance, and symptom scores

  .

• Primary Mitochondrial Myopathy: Clinical trials showed enhanced ATP production and improved mobility outcomes, although benefits are condition-specific

  .

• Cognitive and Neuroprotective Effects: Preclinical studies show SS-31 may improve spatial memory, synaptic function, neurovascular coupling, and reduce β-amyloid and oxidative stress in neurodegenerative models

  
  

• Muscle Function and Endurance: Animal studies indicate improved skeletal muscle ATP, fatigue resistance, and treadmill performance. Human trials demonstrated dose-dependent enhancements in walking distance in mitochondrial disease patients

  .

• Cardiovascular Research: Preclinical data show potential cardioprotection via improved mitochondrial integrity, reduced ROS, and preserved cristae in heart failure and ischemia-reperfusion models

  .

• Additional Research Areas: Investigated for Type 2 Diabetes, kidney injury models, aging, and neurodegenerative diseases, though these uses remain experimental